Observational Study Biomarkers Osteoarthritis China
ClinicalTrials.gov Studies
Summary
ClinicalTrials.gov registered an observational study (NCT07544823) titled 'Screening for Biomarkers of Osteoarthritis' conducted in China, posted April 22, 2026. The study intends to collect blood samples from osteoarthritis patients and suspected patients at a tertiary hospital orthopedic outpatient department, using diagnostic and differential diagnostic tests to verify candidate biomarkers. Researchers aim to screen biomarkers with favorable validity and reliability to support early prevention, early diagnosis, and individualized intervention for osteoarthritis.
“In China, the number of patients with osteoarthritis is projected to exceed 200 million by 2044, resulting in a continuously growing demand for medical resources and escalating economic burden.”
About this source
GovPing monitors ClinicalTrials.gov Studies for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 686 changes logged to date.
What changed
ClinicalTrials.gov registered a new observational study (NCT07544823) under the condition of Osteoarthritis (OA) on April 22, 2026. The study is described as an observational cohort targeting OA patients and suspected patients at a tertiary hospital orthopedic outpatient department in China, with the goal of collecting blood samples and applying diagnostic and differential diagnostic tests to verify the clinical application value of previously reported candidate biomarkers. Healthcare providers and clinical researchers in the osteoarthritis and biomarker diagnostic space should be aware of this study's enrollment criteria and methodology as a reference for similar biomarker validation programs.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Screening for Biomarkers of Osteoarthritis
Observational NCT07544823 Kind: OBSERVATIONAL Apr 22, 2026
Abstract
Osteoarthritis (OA) is the most prevalent degenerative joint disease worldwide, which causes pain, loss of joint function and declined quality of life, and ranks as the leading cause of disability among individuals aged over 60 years. In China, the number of patients with osteoarthritis is projected to exceed 200 million by 2044, resulting in a continuously growing demand for medical resources and escalating economic burden.Nevertheless, the lack of effective biomarkers for early diagnosis leads to advanced disease conditions at the time of initial medical consultation and delayed treatment. This project intends to collect blood samples from OA patients and suspected patients in the orthopedic outpatient department of a tertiary hospital. Diagnostic and differential diagnostic tests will be adopted to verify the clinical application value of previously reported candidate biomarkers, so as to screen out biomarkers with favorable validity and reliability. The research findings are expected to provide data support and theoretical basis for the early prevention, early diagnosis and individualized intervention of osteoarthritis.
Conditions: Osteoarthritis (OA)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.